Correlation between Troponin I Levels and Location of Acute Myocardial Infarction in ST-Elevation Myocardial Infarction Patients
DOI:
https://doi.org/10.37275/bsm.v9i1.1172Keywords:
Acute myocardial infarction, Cardiac biomarkers, Infarct location, ST-elevation myocardial infarction, Troponin IAbstract
Background: Acute myocardial infarction (AMI) remains a leading cause of mortality in Indonesia. Cardiac troponin I (cTnI) is a highly sensitive and specific biomarker for AMI, and its levels may correlate with infarct location and prognosis. This study investigated the relationship between cTnI levels and the location of myocardial infarction in ST-elevation myocardial infarction (STEMI) patients.
Methods: A cross-sectional study was conducted on 57 STEMI patients admitted to H. Abdul Manap Regional General Hospital in Jambi City from April 2022 to 2024. Patients were consecutively enrolled based on inclusion and exclusion criteria. cTnI levels were measured using a point-of-care testing (POCT) device. The correlation between cTnI levels and infarct location was analyzed using the Pearson correlation test.
Results: The majority of patients were male (78.49%). The highest incidence of AMI was observed in the anterolateral location, with an average cTnI level of 12.16 ng/ml. A strong positive correlation was found between cTnI levels and the location of infarction (r = 0.891, p < 0.05).
Conclusion: Higher cTnI levels are associated with specific AMI locations, particularly anterolateral infarctions. This finding highlights the importance of cTnI measurement in assessing AMI severity and potential prognosis.
Authors
- Tiara Monica1*
- Valentin Widry Enggal1
- 1Department of Clinical Pathology, H. Abdul Manap Regional General Hospital, Jambi, Indonesia
Corresponding author Tiara Monica — tiaramonmon@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
